...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >FORMULATION OF DICLOFENAC SODIUM SUSTAINED RELEASE TABLET USING COPROCESSED EXCIPIENTS OF CROSSLINKED AMYLOSE–XANTHAN GUM AS MATRIX
【24h】

FORMULATION OF DICLOFENAC SODIUM SUSTAINED RELEASE TABLET USING COPROCESSED EXCIPIENTS OF CROSSLINKED AMYLOSE–XANTHAN GUM AS MATRIX

机译:以交联淀粉-黄原胶的共处理赋形剂为基质,配制双氯芬酸钠缓释片剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: This present study was intended to design sustained release tablet containing diclofenac sodium using a matrix of excipient co-processed xanthan gum-crosslinked amylose. Methods: In the previous study, xanthan gum and amylose have been physically and chemically modified by the co-processed and crosslinking method, resulting co-processed excipient xanthan gum-crosslinked amylose are Co-CLA6-XG and Co-CLA12-XG (method A); CL6-Co-A-XG and CL12-Co-A-XG (method B) with each ratio 1:1, 1:2 and 2:1. All excipients had a good swelling index, high viscosity and good gel strength, good characteristics to be used as a matrix for sustained release tablet dosage form. In this study, a tablet with excipient Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG were formulated by direct compression method. The prepared formulations were evaluated for weight variation, thickness, and diameter, hardness, friability, drug content estimation, swelling index, in vitro drug release are within the acceptable standard. Results: The release profile of diclofenac sodium which contained matrix from Co-CLA6-XG (F1–F3), Co-CLA12-XG (F4–F6), CL6-Co-A-XG (F7–F9) and CL12-Co-A-XG (F10–F12) in phospate buffer medium for 8 h, showed that the sustained release profile followed zero order kinetics (F1–F6, F9, F11) and Korsmeyer-Peppas (F7, F8, F10, F12). Formula F1 to F6 tablet formulations could be applied as sustained release tablet formula and could retard drug release up to 16 h. Then, formula F7 to F12 could be applied as sustained release tablet formula and could retard drug release up to 32 h. Conclusion: It may be concluded that coprocessed excipients of crosslinked amylose–xanthan gum can be used for the preparation of sustained release tablets of diclofenac sodium and can retard the drug release for 16 h and 32 h. Keywords : Excipient coprocessed xanthan gum-crosslinked amylose, Matrix, Diclofenac sodium, Sustained release tablet
机译:目的:本研究旨在使用赋形剂共处理黄原胶交联的直链淀粉设计含有双氯芬酸钠的缓释片剂。方法:在先前的研究中,黄原胶和直链淀粉通过共处理和交联方法进行了物理和化学修饰,所得共处理的辅料黄原胶交联的直链淀粉分别为Co-CLA6-XG和Co-CLA12-XG(方法一种); CL6-Co-A-XG和CL12-Co-A-XG(方法B),每种比率为1:1、1:2和2:1。所有赋形剂均具有良好的溶胀指数,高粘度和良好的凝胶强度,良好的特性,可用作缓释片剂剂型的基质。在这项研究中,通过直接压片法配制了辅料为Co-CLA6-XG,Co-CLA12-XG,CL6-Co-A-XG和CL12-Co-A-XG的片剂。评价制备的制剂的重量变化,厚度和直径,硬度,易碎性,药物含量估计,溶胀指数,体外药物释放均在可接受的标准内。结果:双氯芬酸钠的释放曲线包含Co-CLA6-XG(F1-F3),Co-CLA12-XG(F4-F6),CL6-Co-A-XG(F7-F9)和CL12-Co中的基质-A-XG(F10–F12)在磷酸盐缓冲液中的作用8 h,表明缓释曲线遵循零级动力学(F1-F6,F9,F11)和Korsmeyer-Peppas(F7,F8,F10,F12)。配方F1至F6片剂可以用作缓释片剂,并且可以将药物释放延迟至16小时。然后,可以将配方F7至F12用作缓释片剂配方,并且可以将药物释放延迟至32小时。结论:可以得出结论,交联的直链淀粉-黄原胶的共处理赋形剂可用于制备双氯芬酸钠的缓释片剂,并且可以将药物释放延迟16小时和32小时。关键词:辅料共处理黄原胶交联的直链淀粉,基质,双氯芬酸钠,缓释片

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号